Tessera Therapeutics

Phase A — Understand the business

Lens 1 · Company Overview

Tessera Therapeutics is a Flagship Pioneering-founded, Cambridge/Somerville-MA private biotech commercializing a genome-engineering modality it calls Gene Writing™ — a third category alongside CRISPR nuclease editing (cut-and-repair) and base/prime editing. Founded inside Flagship Labs in 2018, emerged from stealth July 2020. HQ: 101 South Street, Somerville, MA.

What it actually is — the one-sentence business model: Tessera does not sell a product and has no revenue. It is a platform company whose asset is a delivery-plus-editing toolkit it licenses/partners to pharma and, eventually, would take into the clinic itself. Two technical pillars:

1. The Gene Writers. "Write" therapeutic sequences into the genome without double-strand breaks. Two flavours:

• RNA Gene Writers — based on retrotransposon biochemistry, using target-primed reverse transcription (TPRT) and all-RNA compositions to make substitutions, insertions, deletions, or write whole genes. This is the mechanistic cousin of prime editing but derived from mobile genetic elements rather than a Cas9-RT fusion.
• DNA Gene Writers — based on recombinase/transposase biochemistry, engineered to integrate large ("exon-length or whole-gene") payloads.

1. The delivery platform. Proprietary lipid nanoparticles (LNPs) engineered for extra-hepatic delivery — specifically to hematopoietic stem cells (HSCs) and T cells in vivo. This is the harder and arguably more valuable half of the company (see Lens 3).

Key "products" (pipeline assets):

• TSRA-196 — lead program, in vivo editor for alpha-1 antitrypsin deficiency (AATD), corrects the SERPINA1 Z-allele mutation; FDA IND cleared Jan 12 2026; partnered with Regeneron.
• In vivo sickle cell disease (SCD) program — extra-hepatic LNP to HSCs; preclinical (NHP).
• In vivo CAR-T applications — preclinical.
• HIV cure — early research, grant-funded.

Customers / suppliers / competitors. No commercial customers (pre-revenue). Its one "customer" today is effectively its partner, Regeneron, which is funding and will commercialize the lead asset. Suppliers: standard LNP lipid/nucleic-acid CDMO supply chain (not disclosed; no facilities of its own to close per the layoff notice). Competitors: the entire genetic-medicine field — Beam (base editing), Prime Medicine (prime editing), Intellia (in vivo CRISPR), CRISPR Therapeutics, plus RNA-editing (Wave, AIRNA, Korro) and RNAi (Arrowhead/Takeda) in its lead indication.

Contract structure / payment terms. The economically load-bearing contract is the Regeneron collaboration (Dec 2025): $150M upfront-plus-equity, up to $125M near/mid-term milestones, 50/50 worldwide cost and profit split, Tessera leads first-in-human, Regeneron leads global development + commercialization. This is a risk-and-reward-sharing structure, not a clean royalty license — Tessera keeps half the upside but must fund half the (large) global development bill.

Lens 2 · Supply Chain

Map: IP origin → platform → delivery → target tissue → patient, with the (private-company-limited) named stakeholders.

• Upstream — IP & discovery. Flagship Pioneering (originator; licensed its 2018 IP estate to Tessera) → Flagship Labs founding scientists (von Maltzahn, Rubens, Citorik). The moat's raw material is licensed Flagship patents on RNA/DNA Gene Writing.
• Platform inputs. Synthetic biology reagents, mRNA/RNA synthesis, and LNP lipid components — sourced from the standard genetic-medicine CDMO/reagent supply chain (specific vendors not disclosed; Tessera runs labs, not commercial manufacturing — "no facilities will close" per the layoff, implying it is not vertically integrated into commercial-scale GMP).
• The company — Somerville MA; performs discovery, editor + LNP engineering, IND-enabling tox, and (now) will run the Phase 1/2.
• Delivery — the chokepoint. The extra-hepatic LNP is the single-source dependency and the company's crown jewel; in vivo HSC/T-cell delivery is the field's unsolved problem (see Lens 3). Liver-targeted LNP (the AATD/TSRA-196 route) is more commoditized — the liver is the "easy" LNP target the whole field can reach.
• Downstream — commercialization. For the lead asset this is Regeneron (global dev + commercial). For SCD/CAR-T/HIV, no commercial partner yet — Tessera would need a buyer or its own build.
• End customer. Patients (AATD: ~200,000 PiZZ-genotype in US+Europe; SCD: ~100,000 US).

Chokepoints / single-source: (1) the extra-hepatic LNP delivery tech — irreplaceable, undisclosed, the whole differentiation; (2) the Flagship IP license — a governance dependency on its own founder-investor; (3) post-layoff, execution capacity itself is now a constrained input — a 35%-smaller team must run its first-ever clinical trial.

Lens 3 · Competitive Advantages (moats)

The moat is delivery, not editing. Every credible gene-editing company can now edit; the differentiator in 2026 is where in the body you can reach in vivo. Tessera's durable advantages, ranked:

1. Extra-hepatic in vivo LNP to HSCs — potentially field-leading. In NHP for SCD, a single dose achieved ~85% of long-term HSCs with ≥1 allele edited on single-cell analysis, "exceeding the anticipated curative threshold". If this translates to humans, it collapses the entire ex-vivo cell-therapy value chain (no myeloablative conditioning, no apheresis, no cell manufacturing) — that is a genuine platform moat. This is the single most valuable and most differentiated thing Tessera owns. Caveat: NHP ≠ human; unproven clinically.
2. A distinct modality (TPRT / mobile-element biochemistry). Gene Writing is mechanistically differentiated from Cas9-based prime editing (Prime Medicine) — writes large payloads without DSBs, all-RNA cargo. First-ever IND for an in vivo TPRT editor (Jan 2026) is a real first-mover credential.
3. IP estate. Licensed Flagship patents from 2018 seminal filings; von Maltzahn is inventor on 200+ patents/applications. Breadth is real but the specifics and freedom-to-operate vs. Broad/prime-editing patents are not public — cannot verify the estate is unencumbered.
4. Regeneron validation + capital. A top-tier pharma putting $150M and its commercial machine behind the lead asset is third-party validation of the platform's credibility.

Bargaining power. Weak-to-moderate and deteriorating. As a pre-revenue private that just cut 35% of staff and handed its lead asset to a partner, Tessera needs Regeneron more than Regeneron needs Tessera. The 50/50 split (rather than a rich royalty) reflects that Tessera lacked the balance sheet to go it alone. Its leverage rests entirely on the LNP-delivery tech being genuinely hard to replicate.

Lens 4 · Segments

n/a — private, pre-revenue. No revenue, EBITDA, or earnings to segment; segments.csv is empty seed. The economically meaningful "segmentation" is by program, covered in Lens 5 (pipeline). Geographic split is likewise n/a — the only geography that matters operationally is the Phase 1/2 trial footprint: US + Australia.

---

Phase B — Measure performance (+clinical + +private overlays applied)

Lens 5 · Pipeline by phase (clinical overlay — replaces "Earnings Result")  +  Funding & valuation trajectory (private overlay)

The asset table IS the company:

Provenance: pipeline status; TSRA-196 IND; SCD NHP data; HIV grant.

The one clinical fact that matters: TSRA-196 is the first in vivo TPRT-based genome editor to clear an IND — Tessera has crossed from platform-preclinical into a clinical-stage company (Phase 1/2, open-label, single IV, US+AU, safety + AAT expression/function biomarkers). Note: the brief's framing of Tessera as "pre-clinical frontier bio" is now stale — as of Jan 2026 it is clinical-stage (initiating), for one partnered asset.

Funding & valuation trajectory (private overlay):

• Total private capital raised ≈ $610M across rounds, plus the $150M Regeneron upfront/equity.
• Last priced valuation: not publicly disclosed. Forge/secondary marks exist but no reliable number is sourceable — n/a. Do not infer a valuation.
• Burn signal — the critical read: the Jan 2026 35% layoff (90 of ~250 → ~160 heads) alongside a $50M-only 2024 round (vs. $230M–$300M prior rounds) tells you cash was tightening and the company restructured around Regeneron-funded survival rather than continuing to fund a broad multi-program platform off its own balance sheet.

Lens 6 · Founder / management communications (private overlay — no earnings calls)

No public earnings calls (private). Sentiment is read from CEO interviews + press-release tone.

• Tone shift over time is stark and readable in the artifacts: 2023–2025 releases were platform-expansive ("advancements across Gene Writing and delivery," multiple programs, NHP proof-of-concept). The Dec 2025 → Jan 2026 sequence inverts that: a single lead partnership (Regeneron), a single IND (AATD), and a 35% cut. Management pivoted the narrative from "a platform with many shots on goal" to "one clinical asset, executed with a partner."
• Recurring phrases: "write in the code of life," "at the source," "one-time," "in vivo," "curative threshold." What they stopped saying: the breadth language ("multiple therapeutic programs for clinical development" from the Series C era) is conspicuously de-emphasized post-restructuring.
• CEO Severino's public framing (2026 CEO chats) leans on the first-in-class TPRT IND and the delivery platform as the durable asset.

Lens 7 · Cap table & secondary marks (private overlay) + Mechanism comps (clinical overlay)

Cap-table quality — an IPO-proximity tell. The syndicate is unusually blue-chip for a preclinical private: two sovereign wealth funds (ADIA, QIA), a US state permanent fund (Alaska), SoftBank Vision Fund 2, and — critically — crossover public-market investors T. Rowe Price and Cormorant. A T. Rowe / Cormorant entry is exactly the crossover-fund signature that historically precedes an S-1. However, that signal is now stale (2022) and contradicted by 2024–2026 events: a small $50M round, a 35% layoff, and a partnership-for-survival. Secondary marks are not reliably sourceable (n/a); do not infer a current valuation from the 2022 syndicate.

Mechanism comps (the right peer frame — by modality, not P/E). For a private with no financials, the useful comps are the public gene-editing peers whose market caps price the modality:

Read: the public in-vivo peers span ~$630M (PRME) to ~$3.4B (BEAM). Prime Medicine — the closest mechanistic analog (also a novel large-payload editor, also just entering in vivo Phase 1/2) — carries only ~$632M despite being public and de-risked into the clinic. That is the sobering anchor: the market is currently valuing novel-editor platforms cheaply even after clinical entry. A Tessera IPO into this tape would face a skeptical bid.

Lens 8 · Catalyst / event history (price-catalyst lens, adapted to a private)

No stock, so "catalysts" are the funding/data/partnership events that repriced the company's narrative:

• Jul 2020 — emergence from stealth.
• Jan 2021 — $230M+ Series B (SoftBank/Alaska/QIA) — narrative peak, platform ascendant.
• Apr 2022 — $300M Series C (ADIA/T. Rowe/Cormorant) — crossover-fund IPO-runway signal.
• Jan 2023 — NHP proof-of-concept data — first big technical de-risking.
• Dec 2024 — $50M venture round — the tell that momentum cooled (10–15% the size of prior rounds).
• Dec 1 2025 — Regeneron $150M AATD collaboration — the pivot to partnered execution.
• Jan 12 2026 — twin event: FDA IND clearance (TSRA-196) and 35% layoff, same day — the defining inflection: clinical entry bought by strategic contraction.
• Mar 2026 — HIV-cure grant.
• May 2026 — updated SCD/CAR-T NHP data (85% LT-HSC editing) at ASGCT 29.

Pattern: the market (here, private investors + partners) reacts to two things — delivery-platform data and capital events. The story compounded on data through 2023, then de-rated on the funding environment (2024) and re-based around a partner (2025–26). The next repricing catalyst is binary: first human TSRA-196 data.

---

Phase C — Judge people & books

Lens 9 · Management

• Michael Severino, M.D. — CEO (since 2022). Heavyweight operator hire: former Vice Chairman & President of AbbVie (ran R&D + corporate strategy), before that SVP Global Development & CMO at Amgen; credited on 10+ approved therapies. Track record: genuine late-stage development and commercialization pedigree — exactly the profile you want steering a first-IND-to-clinic transition. His hiring of a big-pharma R&D chief into a preclinical Flagship startup was itself a signal of clinical ambition.
• Geoffrey von Maltzahn, Ph.D. — Co-founder & Board Chair; Flagship General Partner. MIT-trained biological engineer, serial Flagship company-founder, inventor on 200+ patents/applications. The scientific-founder credibility anchor. Dual role (Flagship GP + board chair + IP licensor) is a related-party structure — see Lens 10.
• David Davidson — Chief Medical/Development Officer (ex-bluebird bio; deep gene-therapy clinical experience). Michael Holmes — CSO (ex-Sangamo, ex-Ambys) — genome-editing veteran.
• Tenure & skin in the game: founder-led at the board (von Maltzahn since 2018); professional-manager CEO since 2022. Insider ownership specifics: n/a — private, not disclosed. Flagship is the controlling shareholder.
• Capital-allocation history: raised ~$610M and deployed it into a broad multi-program platform; when the environment turned, executed a disciplined narrowing — partnered the lead asset (bringing in $150M of non-dilutive-ish capital + a commercial partner) and cut 35% of staff to extend runway. This is defensible, even shrewd, capital allocation under stress — but it is also an admission that the go-it-alone platform strategy was not fundable in 2024–26.
• Archetype: VC-incubated platform (Flagship "hypothesis-driven" company creation) with a professional-manager CEO bolted on for the clinical era. Implication: the science is founder/VC-driven; execution risk sits with a capable but recently-shrunken team.
• Red flags: (1) the Flagship-as-founder-investor-IP-licensor-board-chair concentration; (2) a 35% layoff is a real negative signal about pre-partnership cash; (3) no independent public financials to audit any of it.

Lens 10 · Forensic Red Flags (re-pointed to trial-integrity + going-concern + related-party, per clinical overlay)

No audited financials, income statement, or cash-flow statement exist to run standard forensic tests — the absence of auditable books is itself the primary caveat (label all: unaudited per public sources). What can be assessed:

• Going-concern / runway (the material risk). The 35% layoff (Jan 2026) plus a shrunken 2024 round ($50M vs. $300M) point to cash pressure pre-Regeneron. The Regeneron $150M + 50/50 cost-share materially de-risks the lead program's funding but does not fund the rest of the platform (SCD/CAR-T/HIV). Runway figure: n/a — not disclosed. Assume the non-partnered pipeline is now capital-starved.
• Related-party structure. Flagship Pioneering is simultaneously founder, largest shareholder, IP licensor, and board chair's employer (von Maltzahn is a Flagship GP). The IP license terms between Flagship and Tessera are not public — a classic related-party dependency where royalty/milestone economics flow back to the controlling investor. Not evidence of wrongdoing; a governance concentration to underwrite.
• Trial-design / data integrity. All efficacy claims to date are preclinical (mice, NHP), company-disclosed via conference abstracts, not peer-reviewed pivotal data. The "85% LT-HSC edited / exceeding curative threshold" figure is a company single-cell readout in NHP — impressive but unaudited and not yet human. Standard preclinical-optimism discount applies.
• SBC / dilution: n/a — private, not disclosed.

Regulatory findings (required sub-section).

• SEC (EDGAR LR + AAER): None — Tessera has no CIK (private, not an SEC filer); no EDGAR enforcement search is possible.
• Non-SEC enforcement (FTC/DOJ/FDA/CFPB): web search for "Tessera Therapeutics" (FTC OR DOJ OR FDA OR consent decree OR settlement OR fine OR penalty) enforcement surfaced no material adverse enforcement actions. The only FDA interaction found is favorable — the Jan 2026 IND clearance for TSRA-196. (Note: a distinct company, "Tessera" in DNA-data-storage, exists — not this issuer; no findings conflated.)
• Item 3 (Legal Proceedings): n/a — no 10-K exists.
• Conclusion: No material regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER — not applicable, no CIK), web search, and the absence of any 10-K, as of 2026-07-06. All private-company findings labeled unaudited per public sources.

Added (clinical overlay) — Science & exclusivity. Mechanism validation: TPRT/mobile-element Gene Writing is scientifically credible and peer-recognized as a distinct modality (first in vivo TPRT IND is field-acknowledged). IP: broad Flagship estate, but freedom-to-operate vs. the Broad Institute / prime-editing patent thicket is unverified — a real exclusivity question for any large-payload RNA-templated editor. Reimbursement path (AATD): a one-time curative would command premium pricing but faces the durability-evidence bar every one-time genetic medicine now faces.

---

Phase D — Project & stress-test

Lens 11 · IPO-readiness & path-to-tradeable (private overlay) + rNPV framing (clinical overlay)

IPO readiness — the be-early payoff lens.

• Stage: clinical-stage (Phase 1/2 initiating), platform-narrowed, partner-funded lead asset. Not S-1-ready today.
• What unlocks an S-1: (1) first human TSRA-196 safety + AAT-biomarker data (the credibility gate — an in-human TPRT editor working would be a genuinely novel IPO story); (2) a broader funding environment for pre-commercial genetic medicine (currently poor — see PRME at ~$632M); (3) evidence the extra-hepatic LNP translates from NHP to human (the SCD program is the real platform value).
• Estimated window: not before late 2027–2028. The 2022 crossover syndicate (T. Rowe/Cormorant) would support an IPO, but the 2024–26 contraction pushed the timeline right.
• private-watch.json write-back: NOT PERFORMED — Tessera has no entry in the ledger (28 entries, none tessera), so stage/ipo_readiness/catalyst/dossier could not be updated. Open item: add a tessera entry (suggested: stage: clinical-Phase1/2-initiating, ipo_readiness: low-medium, catalyst: first-in-human TSRA-196 data, dossier: companies/tessera/deep-dive-2026-07-06.md) so privates.ts shows it dossier-warm.

rNPV framing (clinical overlay — every input labeled, illustrative): A rigorous rNPV is not sourceable (no disclosed peak-sales guidance, no valuation). Directionally, for TSRA-196/AATD, Tessera's economics are half of the program (50/50 with Regeneron), against an AATD-genetic-medicine opportunity where Beam is already ahead. Illustrative only — n/a for a hard number. The binary that actually matters is not EPS but runway-to-catalyst: does Regeneron's cost-share carry TSRA-196 to first human data? Yes, per the 50/50 structure — the lead program's runway is effectively underwritten by Regeneron; the platform's runway (unpartnered programs) is the open question.

Brier forecast (the trackable binary): TSRA-196 reports its first-in-human clinical data (any AAT-biomarker readout) by 2027-12-31 — p ≈ 0.60. (Not logged via forecast.ts — this is the unattended --watchlist path; no forecast create per skill rules. Recorded here for Connor to log if he takes a view.)

No EPS projection — pre-revenue private; an EPS line would be fabrication. n/a — pre-revenue.

Lens 12 · Bull vs Bear

Bull case. Tessera owns the two things the gene-editing field is short of: a genuinely differentiated large-payload, break-free editing modality (TPRT) and — more valuably — a best-in-class extra-hepatic LNP that hits HSCs in vivo (85% LT-HSC editing in NHP). If in-vivo HSC delivery works in humans, it obsoletes the entire ex-vivo cell-therapy stack (Casgevy-style conditioning, apheresis, manufacturing) — a multi-billion-dollar disruption of sickle cell/thalassemia economics. It just posted the first in vivo TPRT IND, has a top-tier pharma (Regeneron) sharing risk and validating the platform, a blue-chip crossover/sovereign cap table primed for an eventual IPO, and a proven big-pharma operator (Severino) to run the clinic. The layoff is capital discipline, not distress — it concentrated resources behind the highest-value, now-funded program.

Bear case (2–3 permanent-impairment risks).

1. It brought a knife to a gunfight in its own lead indication. TSRA-196/AATD is entering FIH in 2026 — but Beam's BEAM-302 already has human clinical proof-of-concept in AATD and picked its pivotal dose (60mg) in Mar 2026, with Wave (RNA editing) and Arrowhead/Takeda (RNAi, Phase 3) also in the space. Tessera chose to lead with the indication where it is most behind. If BEAM-302 reaches market first with durable data, TSRA-196's commercial window narrows structurally.
2. The real asset (extra-hepatic LNP / SCD) is unfunded and unproven in humans. The platform's genuine differentiation lives in the preclinical, unpartnered SCD/HSC program — which the layoff and the AATD-focus just deprioritized in capital terms. The value driver is the least-funded program; the funded program is the least-differentiated one.
3. Platform-company-as-preclinical-private in a hostile tape. The comps say it all: Prime Medicine — public, in the clinic, mechanistically similar — trades at ~$632M. The market is pricing novel-editor platforms cheaply. A Tessera IPO or up-round faces a skeptical bid, and the 35% cut + shrunken 2024 round signal that going alone was not fundable.

Pre-mortem (18 months out, thesis broke): Beam's AATD data matured toward filing while TSRA-196's first human readout slipped and/or showed weaker-than-NHP editing; the unpartnered SCD program stalled for lack of capital; no IPO window opened; Regeneron's enthusiasm was contained to the one asset. Tessera becomes a one-partnered-program company living on Regeneron's cost-share — a much smaller outcome than "the third gene-editing platform."

Multiples too high? No public multiple exists. Relative to the mechanistic comp (PRME ~$632M), any private mark north of ~$1–2B would look rich given Tessera is less clinically advanced. Valuation: n/a — not disclosed; peer-anchored skepticism warranted.

Contrarian view (what the market is refusing to see): the crowd reads "35% layoff + partnered lead asset" as distress. The more interesting read: Regeneron may have effectively taken a call option on the entire platform for $150M — and the thing worth owning was never TSRA-196/AATD (the crowded, half-owned program) but the extra-hepatic HSC LNP. If that delivery tech works in humans, whoever controls it wins in vivo — and it is currently mispriced to ~zero inside a distressed-looking private.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case:

• Structural break in the business model: Tessera is a platform with no product, no revenue, one half-owned clinical asset, and a 35%-smaller team. Its entire equity value rests on unproven-in-human delivery tech. A single indication (AATD) is both its most-advanced and most-contested program.
• Concentration: revenue is zero; "value" concentrates in (a) the Regeneron relationship — if Regeneron walks (as GSK walked from Wave's AATD asset ), the lead program loses its funder and commercializer overnight — and (b) one unfunded preclinical delivery platform.
• Why the moat is weaker than bulls think: the field is converging on in vivo LNP delivery — Prime Medicine published in vivo prime editing via LNP; Intellia has in vivo CRISPR in Phase 3; Beam has in vivo AATD in the clinic. Tessera's LNP edge is NHP-stage and undisclosed — no independent, peer-reviewed human confirmation. Delivery advantages have a habit of shrinking as the whole field's LNP chemistry improves.
• Most dangerous competitor bulls underestimate: Beam. It is ahead in Tessera's own lead indication, better-capitalized (~$3.4B), public, and moving BEAM-302 to pivotal. Tessera picked a fight it is losing on the clock.
• Worst capital-allocation / governance: the Flagship-as-everything structure (founder + top shareholder + IP licensor + board chair's fund) with undisclosed license economics; a $50M-only 2024 round; and a layoff timed to the same press cycle as the IND (burying bad news under good).
• What must hold for any bull mark: (1) extra-hepatic HSC delivery translates to humans; (2) TSRA-196 beats or matches Beam on data/timeline despite starting behind; (3) the biotech IPO/financing window reopens. All three are uncertain; #2 is arguably already lost.
• If growth (here: clinical progress) disappoints 20–30%: a delayed or weak first-in-human TSRA-196 readout, with no IPO window, would leave Tessera dependent on Flagship/Regeneron bridge capital and could force a down-round or a fire-sale of the platform.
• Single permanent-impairment scenario (plausibility): in-human editing efficiency / durability materially undershoots the NHP 85% figure (a common preclinical-to-clinical fall-off), simultaneously undercutting the AATD program and the platform's core delivery claim. Plausibility: moderate. This is the scenario that kills both the drug and the platform thesis at once.

Lens 14 · Management Questions (ordered by information value)

1. What is the in-human editing efficiency and durability of TSRA-196 to date, and how does it compare to the ~85% LT-HSC / NHP benchmark? (The whole thesis rides here.)
2. Does the Regeneron 50/50 collaboration fully fund TSRA-196 to first-in-human data and beyond, and what are the specific triggers by which either party could terminate?
3. What is Tessera's current cash runway (months) for the unpartnered pipeline (SCD, CAR-T, HIV) after the Jan 2026 restructuring?
4. The company's differentiation is extra-hepatic HSC LNP delivery — why lead the clinic with a liver-targeted, crowded indication (AATD) instead of the SCD program where the platform edge is greatest?
5. What are the exact economic terms of the Flagship IP license (royalties, milestones, field/exclusivity), and how do they affect Tessera's net economics on each program?
6. What is your freedom-to-operate position vs. the Broad Institute / prime-editing patent estates for large-payload, RNA-templated in vivo editing?
7. Given Beam's BEAM-302 clinical POC and pivotal-dose selection in AATD, what is TSRA-196's differentiated basis to compete or win — on efficacy, durability, safety, or dosing?
8. What conditioning/immunosuppression, if any, does the in vivo HSC approach require, and what is the off-target / genotoxicity profile of TPRT writing in HSCs?
9. What is the path and timeline to an S-1, and what data or market conditions do you consider prerequisites?
10. Post-layoff, do you retain the clinical-operations and manufacturing capacity to run a multi-national Phase 1/2 without a CDMO/partner bottleneck?
11. What is the immunogenicity risk of the retrotransposon-derived Gene Writer proteins on redosing, and is the platform a one-shot or redoseable modality?
12. Beyond Regeneron, what is the business-development strategy for the platform — partner each program, or build toward independent commercialization?
13. How large and how encumbered is the owned vs. licensed portion of the IP estate — what does Tessera own outright vs. license from Flagship?
14. What would you need to see from the SCD program to prioritize it for the next capital, and who would fund it?
15. What is the single assumption most likely to be wrong in your current plan, and what is the earliest signal you would get that it is failing?

---